Capricor licenses exosome platform tech from Johns Hopkins
Biotech company Capricor Therapeutics announced it has signed an exclusive worldwide licensing agreement with Johns Hopkins University to include engineered exosomes for vaccines and therapeutics in its exosome technology portfolio. Read More
Sirnaomics, Walvax team up on anti-influenza siRNA
Sirnaomics Biopharmaceuticals has entered into a partnership with Walvax Biotechnology for the co-development of STP702, its anti-influenza short interfering RNA therapeutic candidate. Read More
Thermo Fisher to sell Progen primary antibodies
Gene therapy tools manufacturer Progen Biotechnik has signed a nonexclusive distribution agreement with Thermo Fisher Scientific. Read More
Altru Health adopts clinical trial AI from Deep Lens
Deep Lens and Altru Health System have announced a strategic collaboration that will deploy the Viper artificial intelligence (AI)-based clinical trial matching software from Deep Lens into the Altru Health System network. Read More
AMRI strategically expands to produce rare disease products
Albany Molecular Research (AMRI) has expanded access to its accelerated solutions platform from research and development to manufacturing for orphan and rare disease products. Read More
Brii COVID-19 mAb combo advances to phase III NIH trial
Brii Biosciences announced that it is enrolling patients in a phase III trial of its monoclonal antibody (mAb) combination therapy, BRII-196 and BRII-198, after meeting phase II safety and efficacy criteria. Read More
Taconic Biosciences releases COVID-19 mouse model
Taconic Biosciences announced it has developed a human angiotensin-converting enzyme 2 AC22 lethality-resistant transgenic mouse model that will permit the study of sublethal COVID-19 infection. Read More
Bavarian Nordic posts positive preclinical data for its COVID-19 vaccine
Bavarian Nordic reported that additional preclinical data confirms its COVID-19 vaccine candidate can induce neutralizing antibodies against SARS-CoV-2 variants. Read More
Brooklyn licenses mRNA cell reprogramming platform
Brooklyn ImmunoTherapeutics has acquired an exclusive license for messenger RNA (mRNA) gene editing and cell therapies technology from Factor Bioscience and Novellus Therapeutics as an exercise of a previously announced option. Read More
Repertoire, Yale partner to study T-cell contributions to MS
Repertoire Immune Medicines is collaborating with Yale University to understand the basis of cellular immunity of multiple sclerosis (MS) by determining what types of antigens are activating T cells in patients. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
